Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Author(s):

Alessandra Battaglia ◽

Alexia Buzzonetti ◽

Marco Fossati ◽

Giovanni Scambia ◽

Andrea Fattorossi ◽

...

Keyword(s):

Ovarian Cancer ◽

Combination Therapy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Immune Correlates ◽

Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Cancer Immunology Immunotherapy ◽

10.1007/s00262-020-02537-4 ◽

2020 ◽

Vol 69 (7) ◽

pp. 1389-1389

Author(s):

Alessandra Battaglia ◽

Alexia Buzzonetti ◽

Marco Fossati ◽

Giovanni Scambia ◽

Andrea Fattorossi ◽

...

Keyword(s):

Ovarian Cancer ◽

Combination Therapy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Immune Correlates ◽

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

BMC Medicine ◽

10.1186/1741-7015-8-3 ◽

2010 ◽

Vol 8 (1) ◽

Cited By ~ 27

Author(s):

Dimitrios Bafaloukos ◽

Helena Linardou ◽

Gerasimos Aravantinos ◽

Christos Papadimitriou ◽

Aristotelis Bamias ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Pegylated Liposomal Doxorubicin ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive ◽

Supplementation in cancer patients receiving chemo or chemo/radiation therapy: A multicentric, randomized phase Ii study

Clinical Nutrition ◽

10.1016/j.clnu.2018.06.2082 ◽

2018 ◽

Vol 37 ◽

pp. S310

Author(s):

A.A. Faccio ◽

C. Mattos ◽

E.S. Santos ◽

N.R. Malta ◽

R.P. Moreira ◽

...

Keyword(s):

Radiation Therapy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of Oncology ◽

10.1093/annonc/mds132 ◽

2012 ◽

Vol 23 (12) ◽

pp. 3069-3074 ◽

Cited By ~ 94

Author(s):

E. Alba ◽

L. Calvo ◽

J. Albanell ◽

J.R. De la Haba ◽

A. Arcusa Lanza ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Neoadjuvant Treatment ◽

Luminal Breast Cancer ◽

Breast Cancer Patients ◽

P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.

10.1158/0008-5472.sabcs11-p5-19-02 ◽

2011 ◽

Author(s):

L Vahdat ◽

P Gopalakrishna ◽

AA Garcia ◽

C Vogel ◽

C Pellegrino ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Eribulin Mesylate ◽

APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT): Results from the expanded combination therapy cohort

Annals of Oncology ◽

10.1093/annonc/mdz249.012 ◽

2019 ◽

Vol 30 ◽

pp. v363

Author(s):

E. Farè ◽

D. Raggi ◽

P. Giannatempo ◽

M. Colecchia ◽

G. Calareso ◽

...

Keyword(s):

Combination Therapy ◽

Germ Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Germ Cell Tumours ◽

Open Label ◽

BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdy285.209 ◽

2018 ◽

Vol 29 ◽

pp. viii357

Author(s):

N. Colombo ◽

O. Nicoletto ◽

P. Benedetti Panici ◽

G. Tognon ◽

A.A. Lissoni ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Intermittent Schedule ◽

Platinum Resistant ◽

Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study

Annals of Oncology ◽

10.1016/s0923-7534(20)34332-5 ◽

2012 ◽

Vol 23 ◽

pp. ixe17

Author(s):

D. Berton-Rigaud ◽

J. Alexandre ◽

M. Provansal ◽

A. Casado ◽

A. Gonzalez Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Two Stage ◽

Preliminary Results ◽

Resistant Refractory ◽

Platinum Resistant

PRELIMINARY RESULTS ON THE IMPACT OF HYPOFRACTIONATED RADIOTHERAPY IN CARDIAC TOXICITY (CARDIAC FUNCTION) IN EARLY STAGED LEFT SIDED BREAST CANCER PATIENTS: A PROSPECTIVE RANDOMIZED PHASE II STUDY

Radiotherapy and Oncology ◽

10.1016/s0167-8140(11)71807-2 ◽

2011 ◽

Vol 98 ◽

pp. S41 ◽

Author(s):

I. Fragkandrea-Nixon ◽

V. Kouloulias ◽

N. Mpaziotis ◽

S. Mpetsou ◽

A. Sotiropoulou-Lontou ◽

...

Keyword(s):

Breast Cancer ◽

Cardiac Function ◽

Cancer Patients ◽

Phase Ii ◽

Cardiac Toxicity ◽

Phase Ii Study ◽

Breast Cancer Patients ◽

Preliminary Results ◽

Randomized Phase Ii ◽

The Impact

5003 ORAL A randomised phase II study of carboplatin plus liposomal doxorubicin (CLD) vs carboplatin plus paclitaxel (CP) in potentially platinum sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71175-8 ◽

2007 ◽

Vol 5 (4) ◽

pp. 312 ◽

Author(s):

H. Linardou ◽

D. Bafaloukos ◽

A. Bamias ◽

I. Xanthakis ◽

H.P. Kalofonos ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Sensitive